New COVID-19 Variant BA.3.2 Spreading Globally: What You Require to Know
A highly mutated variant of SARS-CoV-2, designated BA.3.2, is gaining traction worldwide, prompting increased surveillance efforts. As of February 11, 2026, the variant has been identified in at least 23 countries, including the United States.
BA.3.2: A Significantly Different Strain
BA.3.2 is genetically distinct from the JN.1 lineages, including LP.8.1 and XFG, which have been dominant since January 2024. It boasts approximately 70 to 75 substitutions and deletions in the spike protein gene compared to JN.1. This substantial genetic divergence raises concerns about potential impacts on vaccine effectiveness and prior immunity.
Detection and Spread: Wastewater and Travel Insights
The Centers for Disease Control and Prevention (CDC) has been tracking BA.3.2 through multiple surveillance systems. The first US identification occurred on June 27, 2025, via the Traveler-Based Genomic Surveillance program, detecting the strain in a traveler arriving from the Netherlands. Further analysis revealed the variant in nasal swabs from four US travelers, clinical samples from five patients and wastewater samples from 25 states. Notably, 132 wastewater surveillance samples contained BA.3.2.
Detection rates began to climb in September 2025, with BA.3.2 accounting for roughly 30% of sequences in Denmark, Germany, and the Netherlands between November 2025 and January 2026. In the US, as of February 11, 2026, BA.3.2 comprised 0.19% of the 2,579 genetic sequences collected for national surveillance starting December 1, 2025.
Ongoing Viral Evolution and Sublineages
Researchers have identified two sublineages of BA.3.2 – BA.3.2.1 and BA.3.2.2 – indicating that the virus continues to evolve. The CDC emphasizes the importance of continued genomic surveillance to monitor these changes and assess their potential public health implications.
The CDC notes that detection numbers likely underestimate the true geographic spread of BA.3.2, as many countries have limited genomic detection and surveillance capabilities.
Potential Impact on Immunity
The substantial mutations in the spike protein of BA.3.2 raise the possibility of reduced protection from existing vaccines or prior infection. Further research is needed to determine the extent to which the variant evades immunity.
Frequently Asked Questions
What is genomic surveillance?
Genomic surveillance is the ongoing monitoring of changes in the genetic code of viruses, like SARS-CoV-2, to track their evolution and spread.
How is wastewater surveillance used?
Wastewater surveillance involves testing samples from sewage systems to detect the presence of viruses and track their prevalence in a community.
What are spike proteins?
Spike proteins are structures on the surface of the virus that it uses to enter human cells. They are a key target for vaccines and antibodies.
Stay informed. Continue to follow updates from the CDC and other public health organizations for the latest information on BA.3.2 and other emerging variants. Explore the CDC’s Morbidity and Mortality Weekly Report for detailed findings.
